NCT03240939View on ClinicalTrials.gov

Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

July 7, 2017

Study Completion Date

October 10, 2017

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

Dutasteride 0.5 mg

single dose

DRUG

Tadalafil 5 mg

single dose

DRUG

YY-201

single dose

Trial Locations (1)

05505

Asan Medical Center, Seoul

All Listed Sponsors
lead

Yuyu Pharma, Inc.

INDUSTRY

NCT03240939 - Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil | Biotech Hunter | Biotech Hunter